HC Wainwright Comments on BioXcel Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:BTAI)

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of BioXcel Therapeutics in a research report issued on Monday, April 15th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.51) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.61) EPS.

A number of other research firms also recently commented on BTAI. Bank of America dropped their price objective on BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Canaccord Genuity Group dropped their price target on BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, March 14th. Finally, UBS Group restated a “neutral” rating and set a $4.00 price target (down previously from $9.00) on shares of BioXcel Therapeutics in a research note on Wednesday, February 21st. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, BioXcel Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $16.86.

BioXcel Therapeutics Stock Performance

BTAI opened at $2.55 on Wednesday. BioXcel Therapeutics has a one year low of $1.91 and a one year high of $29.56. The company has a market cap of $77.98 million, a P/E ratio of -0.41 and a beta of 0.40. The business’s 50-day simple moving average is $2.88 and its 200-day simple moving average is $3.17.

BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.22. BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. The business had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.17 million.

Institutional Trading of BioXcel Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in shares of BioXcel Therapeutics in the 4th quarter valued at approximately $176,000. Barclays PLC increased its position in BioXcel Therapeutics by 264.4% during the fourth quarter. Barclays PLC now owns 27,895 shares of the company’s stock worth $82,000 after buying an additional 20,239 shares in the last quarter. Pennant Investors LP purchased a new stake in shares of BioXcel Therapeutics in the fourth quarter valued at $248,000. Tower Research Capital LLC TRC grew its position in BioXcel Therapeutics by 239.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,832 shares of the company’s stock valued at $41,000 after acquiring an additional 9,754 shares during the period. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in BioXcel Therapeutics during the fourth quarter valued at about $112,000. 30.68% of the stock is owned by institutional investors and hedge funds.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.